TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05257759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard management offered in the intensive care unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Standard management offered in the intensive care unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrostimulation
Description: The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the neuromuscular system
Description: Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the neuromuscular system
Description: Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition.
Study: NCT06039592

Intervention type: DRUG
Intervention: Captopril Tablets
Description: 0.3mg/kg, tid

Intervention type: DRUG
Intervention: Metoprolol Oral Tablet
Description: 0.2mg/kg, bid

Intervention type: DRUG
Intervention: Spironolactone Tablets
Description: 2-4mg/kg, bid

Intervention type: DRUG
Intervention: Torsemide Tablets
Description: 0.2-0.5mg/mg, bid

Intervention type: DRUG
Intervention: Torsemide Tablets
Description: 0.2-0.5mg/mg, bid

Intervention type: DRUG
Intervention: Potassium citrate powder
Description: 0.06g/kg, tid

Intervention type: DRUG
Intervention: Potassium citrate powder
Description: 0.06g/kg, tid
Study: NCT04408508

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin 250 MG
Description: Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
Study: NCT06111872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administration described in arm/ group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administration described in arm/ group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Administration described in arm/ group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidin
Description: Administration described in arm/ group description
Study: NCT05768009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Description: • Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Description: • Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.
Study: NCT05717764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection
Description: Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Study: NCT06206122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive rehabilitation training
Description: 1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation training
Description: 1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study: NCT05369494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein infant formula with oligosaccharides
Description: Hydrolyzed protein infant formula with oligosaccharides
Study: NCT05832619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SSRI
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: SSRI
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
Study: NCT06279299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral pelvic lymph node dissection
Description: Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
Study: NCT05414006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-ketamine
Description: S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-ketamine
Description: S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
Study: NCT05438446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)
Description: The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
Study: NCT03752489

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treatment-specific InSight
Description: The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: InSight
Description: The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
Study: NCT04583462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
Study: NCT06002321

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Test
Description: BNP, NT-proBNP and renal function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Test
Description: BNP, NT-proBNP and renal function.
Study: NCT05037539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate 50Mcg/Ml Inj_#1
Description: Injectable Fentanyl in Sublingual Route 50 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Oral Morphine Syrup 2.5 ml ( 5 mg)
Study: NCT05292482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
Study: NCT06182618

Intervention type: OTHER
Intervention: dietary, semaglutide or/and metformin
Description: patients were prescribed dietary and pharmaceuticals for weight loss

Intervention type: OTHER
Intervention: dietary, semaglutide or/and metformin
Description: patients were prescribed dietary and pharmaceuticals for weight loss

Intervention type: OTHER
Intervention: dietary, semaglutide or/and metformin
Description: patients were prescribed dietary and pharmaceuticals for weight loss
Study: NCT06002321

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Test
Description: BNP, NT-proBNP and renal function.
Study: NCT04158973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge
Description: At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
Study: NCT05328284

Intervention type: DEVICE
Intervention: PASCAL leaflet repair system
Description: transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
Study: NCT06241924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Resolution Electroencephalogram (EEG-HR)
Description: Local field potentials (LFP) recording using EEG-HR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereo-electro-encephalography (SEEG)
Description: Local field potentials (LFP) recording using sEEG
Study: NCT05392088

Intervention type: OTHER
Intervention: DATA EXTRACTION
Description: For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status.

Intervention type: OTHER
Intervention: DATA EXTRACTION
Description: For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status.

Intervention type: OTHER
Intervention: FOLLOW-UP
Description: All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.

Intervention type: OTHER
Intervention: FOLLOW-UP
Description: All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
Study: NCT04936113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB-401
Description: Topical
Study: NCT05086341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My COPD
Description: In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
Study: NCT06598189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear-SD
Description: The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
Study: NCT06614777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies and blood extraction
Description: Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area.
Study: NCT06330636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-Allulose
Description: Test breakfast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Saccharin
Description: placebo breakfast